Highlights Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Real-time Estimate Cboe BZX Other stock markets 09:36:22 2024-05-09 am EDT			5-day change	1st Jan Change
4.95 ^USD	+5.32%		-7.11%	-63.50%

May. 07	Transcript : Moleculin Biotech, Inc. - Special Call
May. 07	Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data	May. 07	CI
Sector Update: Health Care Stocks Ease in Afternoon Trading	Apr. 18	MT
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU	Apr. 18	MT
Top Premarket Decliners	Apr. 16	MT
Moleculin Biotech Shares Rise Following Patent Announcement	Mar. 27	MT
Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial	Mar. 25	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Moleculin Biotech to Effect 1-For-15 Reverse Stock Split to Regain Compliance	Mar. 19	MT
Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3	Jan. 24	CI
Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months	Nov. 13	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases	23-09-21	CI
Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin	23-09-18	CI
Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials	23-08-10	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Moleculin Biotech, Inc. Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials	23-03-22	CI
Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer	23-03-09	CI
Moleculin Biotech, Inc. Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia	23-03-01	CI
Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia	23-02-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Highlights

Filters